Insights into the mechanisms involved in the expression and regulation of extracellular matrix proteins in diabetic nephropathy

Current Medicinal Chemistry

Volumn 22, Issue 24, 2015, Pages 2858-2870

  Hu, C ^a   Sun, L ^a   Xiao, L ^a   Han, Y ^a   Fu, X ^a   Xiong, X ^a   Xu, X ^a   Liu, Y ^a   Yang, S ^a   Liu, F ^a   Kanwar, Y S ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diabetic nephropathy; Extracellular matrix; MTOR; Notch; TLRS and small GTPase; WNT

Indexed keywords

BETA CATENIN; COLLAGEN; FIBRONECTIN; JAGGED1; LAMININ; MAMMALIAN TARGET OF RAPAMYCIN; MYELOID DIFFERENTIATION FACTOR 88; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; RAB PROTEIN; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; SCLEROPROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VASCULOTROPIN; WNT PROTEIN; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; NOTCH RECEPTOR; TARGET OF RAPAMYCIN KINASE; TOLL LIKE RECEPTOR;

ARTICLE; DIABETIC NEPHROPATHY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GLOMERULUS BASEMENT MEMBRANE; GLYCEMIC CONTROL; HUMAN; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY INTERSTITIUM; KIDNEY TUBULE; MESANGIUM; MESANGIUM CELL; NONHUMAN; PROTEIN EXPRESSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM;

ANIMALS; BETA CATENIN; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MONOMERIC GTP-BINDING PROTEINS; RECEPTORS, NOTCH; TOLL-LIKE RECEPTORS; TOR SERINE-THREONINE KINASES;

EID: 84940828544     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150625095407     Document Type: Article

References (139)

1. Kanwar, Y.S.; Wada, J.; Sun, L.; Xie, P.; Wallner, E.I.; Chen, S.; Chugh, S.; Danesh, F.R. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood)., 2008, 233(1), 4-11.
2. Murphy, M.; Crean, J.; Brazil, D.P.; Sadlier, D.; Martin, F.; Godson, C. Regulation and consequences of differential gene expression in diabetic kidney disease. Biochem. Soc. Trans., 2008, 36(Pt 5), 941-945.
3. Haider, D.G.; Peric, S.; Friedl, A.; Fuhrmann, V.; Wolzt, M.; Horl, W.H.; Soleiman, A. Kidney biopsy in patients with diabetes mellitus. Clin. Nephrol., 2011, 76(3), 180-185.
4. Kanwar, Y.S.; Sun, L.; Xie, P.; Liu, F.Y.; Chen, S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu. Rev. Pathol., 2011, 6, 395-423.
5. Fioretto, P.; Mauer, M. Histopathology of diabetic nephropathy. Semin. Nephrol., 2007, 27(2), 195-207.
6. Wolf, G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur. J. Clin. Invest., 2004, 34(12), 785-796.
7. Mason, R.M.; Wahab, N.A. Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol., 2003, 14(5), 1358- 1373.
8. Kolset, S.O.; Reinholt, F.P.; Jenssen, T. Diabetic nephropathy and extracellular matrix. J. Histochem. Cytochem., 2012, 60(12), 976- 986.
9. Mariappan, M.M. Signaling mechanisms in the regulation of renal matrix metabolism in diabetes. Exp. Diabetes Res., 2012, 2012, 749812.
10. Stokes, M.B.; Holler, S.; Cui, Y.; Hudkins, K.L.; Eitner, F.; Fogo, A.; Alpers, C.E. Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int., 2000, 57(2), 487- 498.
11. Heilig, C.W.; Deb, D.K.; Abdul, A.; Riaz, H.;James, L.R.; Salameh, J.; Nahman, N.S Jr. GLUT1 regulation of the prosclerotic mediators of diabetic nephropathy. Am. J. Nephrol., 2013, 38(1), 39-49.
12. Miller, C.G.; Pozzi, A.; Zent, R.; Schwarzbauer, J.E. Effects of high glucose on integrin activity and fibronectin matrix assembly by mesangial cells. Mol. Biol. Cell, 2014, 25(16), 2342-2350.
13. Busch, M.; Franke, S.;Ruster, C.; Wolf, G. Advanced glycation end-products and the kidney. Eur. J. Clin. Invest., 2010, 40(8), 742- 755.
14. Kashihara, N.; Haruna, Y.; Kondeti, V.K.; Kanwar, Y.S. Oxidative stress in diabetic nephropathy. Curr. Med. Chem., 2010, 17(34), 4256-4269.
15. Thrailkill, K.M.; Clay Bunn, R.; Fowlkes, J.L. Matrix metalloproteinases: Their potential role in the pathogenesis of diabetic nephropathy. Endocrine, 2009, 35(1), 1-10.
16. Xu, X.; Xiao, L.; Xiao, P.; Yang, S.; Chen, G.; Liu, F.; Kanwar, Y.S.; Sun, L. A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr. Med. Chem., 2014, 21(28), 3244-3260.
17. Kato, M.; Natarajan, R. Diabetic nephropathy-emerging epigenetic mechanisms. Nat. Rev. Nephrol., 2014, 10(9), 517-530.
18. Chiarelli, F.; Gaspari, S.; Marcovecchio, M.L. Role of growth factors in diabetic kidney disease. Horm. Metab. Res., 2009, 41(8), 585-593.
19. Davis, L.K.; Rodgers, B.D.; Kelley, K.M. Angiotensin II- And glucose-stimulated extracellular matrix production: mediation by the insulin-like growth factor (IGF) axis in a murine mesangial cell line. Endocrine, 2008, 33(1), 32-39.
20. Kopan, R.; Ilagan, M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell, 2009, 137(2), 216-233.
21. Morrissey, J.; Guo, G.; Moridaira, K.; Fitzgerald, M.; McCracken, R.; Tolley, T.; Klahr, S. Transforming growth factor-beta induces renal epithelial jagged-1 expression in fibrotic disease. J. Am. Soc. Nephrol., 2002, 13(6), 1499-1508.
22. Chuang, P.Y.; Menon, M.C.; He, J.C. Molecular targets for treatment of kidney fibrosis. J. Mol. Med. (Berl)., 2013, 91(5), 549- 559.
23. Sharma, S.; Sirin, Y.; Susztak, K. The story of Notch and chronic kidney disease. Curr. Opin. Nephrol. Hypertens., 2011, 20(1), 56- 61.
24. Kretzler, M.; Allred, L. Notch inhibition reverses kidney failure. Nat. Med., 2008, 14(3), 246-247.
25. Leask, A. Targeting the jagged/notch pathway: A new treatment for fibrosis? J. Cell. Commun. Signal., 2010, 4(4), 197-198.
26. Sirin, Y.; Susztak, K. Notch in the kidney: development and disease. J. Pathol., 2012, 226(2), 394-403.
27. Zavadil, J.; Cermak, L.; Soto-Nieves, N.; Bottinger, E.P. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelialto- mesenchymal transition. EMBO. J., 2004, 23(5), 1155-1165.
28. Bielesz, B.; Sirin, Y.; Si, H.; Niranjan, T.; Gruenwald, A.; Ahn, S.; Kato, H.; Pullman, J.; Gessler, M.; Haase, V.H.;Susztak K. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J. Clin. Invest., 2010, 120(11), 4040-4054.
29. Murea, M.; Park, J.K.; Sharma, S.; Kato, H.; Gruenwald, A.; Niranjan, T., Si, H.; Thomas, D.B.; Pullman, J.M.; Melamed, M.L.; Susztak, K. Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function. Kidney Int., 2010, 78(5), 514-522.
30. Walsh, D.W.; Roxburgh, S.A.; McGettigan, P.; Berthier, C.C.; Higgins, D.G.; Kretzler, M.; Cohen, C.D.; Mezzano, S.; Brazil, D.P.; Martin, F. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochim. Biophys. Acta., 2008, 1782(1), 10- 21.
31. Hills, C.E.; Squires, P.E. TGF-β-Induced Epithelial-to- Mesenchymal Transition and Therapeutic intervention in Diabetic Nephropathy. Am. J. Nephrol., 2010, 31, 68-74.
32. Loeffler, I.; Wolf, G. Transforming growth factor-beta and the progression of renal disease. Nephrol. Dial. Transplant, 2014, 29(Suppl 1), i37-i45.
33. Choi, M.E. Mechanism of transforming growth factor-beta1 signaling: Role of the mitogen-activated protein kinase. Kidney Int. Suppl., 2000, 77, S53-58.
34. Bonegio, R.; Susztak, K. Notch signaling in diabetic nephropathy. Exp. Cell Res., 2012, 318(9), 986-992.
35. Liu, L.; Gao, C.; Chen, G.; Li, X.; Li, J.; Wan, Q.; Xu, Y. Notch signaling molecules activate TGF- beta in rat mesangial cells under high glucose conditions. J. Diabetes Res., 2013, 2013, 979702.
36. Ahn, SH.; Susztak, K. Getting a notch closer to understanding diabetic kidney disease. Diabetes, 2010, 59(8), 1865-1867.
37. Niranjan, T.; Bielesz, B.; Gruenwald, A.; Ponda, M.P.; Kopp, J.B.; Thomas, D.B.; Susztak, K. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat. Med., 2008, 14(3), 290-298.
38. Lin, C.L.; Wang, F.S.; Hsu, Y.C.; Chen, C.N.; Tseng, M.J.; Saleem, M.A.; Chang, P.J.; Wang, J.Y. Modulation of notch-1 signaling alleviates vascular endothelial growth factor - mediated diabetic nephropathy. Diabetes, 2010, 59(8), 1915-1925.
39. Clevers, H.; Nusse, R. Wnt/beta-catenin signaling and disease. Cell, 2012, 149(6), 1192-1205.
40. Mi, K.; Dolan, P.J.; Johnson, G.V. The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity. J. Biol. Chem., 2006, 281(8), 4787-4794.
41. Maarouf, O.H.; Ikeda, Y.; Humphreys, B.D. Wnt signaling in kidney tubulointerstitium during disease. Histol. Histopathol., 2015, 30(2), 163-71.
42. Kikuchi, A.; Kishida, S.; Yamamoto, H. Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp. Mol. Med., 2006, 38(1), 1-10.
43. Bienz, M. beta-Catenin: A pivot between cell adhesion and Wnt signalling. Curr. Biol., 2005, 15(2), R64-67.
44. Hwang, I.; Seo, E.Y.; Ha, H. Wnt/beta-catenin signaling: A novel target for therapeutic intervention of fibrotic kidney disease. Arch. Pharm. Res., 2009, 32(12), 1653-1662.
45. Cisternas, P.; Vio, C.P.; Inestrosa, N.C. Role of Wnt signaling in tissue fibrosis, lessons from skeletal muscle and kidney. Curr. Mol. Med., 2014, 14(4), 510-522.
46. He, W.; Dai, C.; Li, Y.; Zeng, G.; Monga, S.P.; Liu, Y. Wnt/betacatenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol., 2009, 20(4), 765-776.
47. He, W.; Kang, Y.S.; Dai, C.; Liu, Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J. Am. Soc. Nephrol., 2011, 22(1), 90-103.
48. Surendran, K.; Schiavi, S.; Hruska, K. A. Wnt-dependent β-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J. Am. Soc. Nephrol., 2005, 16, 2373- 2384.
49. Akhmetshina, A.; Palumbo, K.; Dees, C.; Bergmann, C.; Venalis, P.; Zerr, P.; Horn, A.; Kireva, T.; Beyer, C.; Zwerina, J.;Schneider, H.; Sadowski, A.; Riener, M.O.; MacDougald, O.A.; Distler, O.; Schett, G.; Distler, J. H. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat. Commun., 2012, 3, 735.
50. Ho, C.; Lee, P.H.; Hsu, Y.C.; Wang, F.S.; Huang, Y.T.; Lin, C.L. Sustained Wnt/beta-catenin signaling rescues high glucose induction of transforming growth factor-beta1-mediated renal fibrosis. Am. J. Med. Sci., 2012, 344(5), 374-382.
51. Xiao, L.; Wang, M.; Yang, S.; Liu, F.; Sun, L. A glimpse of the pathogenetic mechanisms of Wnt/beta-catenin signaling in diabetic nephropathy. Biomed. Res. Int., 2013, 2013, 987064.
52. Lin, C.L.; Wang, J.Y.; Huang, Y.T.; Kuo, Y.H.; Surendran, K.; Wang, F.S. Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J. Am. Soc. Nephrol., 2006, 17(10), 2812-2820.
53. Pulkkinen, K.; Murugan, S.; Vainio, S. Wnt signaling in kidney development and disease. Organogenesis, 2008, 4(2), 55-59.
54. Lin, C.L.; Wang, J.Y.; Ko, J.Y.; Surendran, K.; Huang, Y.T.; Kuo, Y.H.; Wang, F.S. Superoxide destabilization of beta-catenin augments apoptosis of high-glucose-stressed mesangial cells. Endocrinology, 2008, 149(6), 2934-2942.
55. Mishra, R.; Emancipator, S.N.; Kern, T.; Simonson, M.S. High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. Kidney Int., 2005, 67(1), 82-93.
56. Lin, C.L.; Cheng, H.; Tung, C.W.; Huang, W.J.; Chang, P.J.; Yang, J.T.; Wang, J.Y. Simvastatin reverses high glucose-induced apoptosis of mesangial cells via modulation of Wnt signaling pathway. Am. J. Nephrol., 2008, 28(2), 290-297.
57. Lin, C.L.; Wang, J.Y.; Ko, J.Y.; Huang, Y.T.; Kuo, Y.H.; Wang, F.S. Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangial matrix and renal dysfunction. J. Am. Soc. Nephrol., 2010, 21(1), 124-135.
58. Mu, J.; Pang, Q.; Guo, Y.H.; Chen, J.G.; Zeng, W.; Huang, Y.J.; Zhang, J.; Feng, B. Functional implications of microRNA-215 in TGF-beta1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1. PLoS One, 2013, 8(3), e58622.
59. Zhou, T.; He, X.; Cheng, R.; Zhang, B.; Zhang, R.R.; Chen, Y.; Takahashi, Y.; Murray, A.R.; Lee, K.; Gao, G.; Ma, J.X. Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy. Diabetologia, 2012, 55(1), 255-266.
60. Rooney, B.; O'Donovan, H.; Gaffney, A.; Browne, M.; Faherty, N.; Curran, S.P.; Sadlier, D.; Godson, C.; Brazil, D.P.; Crean, J. CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS. Lett., 2011, 585(3), 531-538.
61. Kawakami, T.; Ren, S.; Duffield, J.S. Wnt signalling in kidney diseases: dual roles in renal injury and repair. J. Pathol., 2013, 229(2), 221-231.
62. Liu, Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol., 2010, 21(2), 212-222.
63. Lee, Y.J.; Han, H.J. Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3beta, Snail1, and beta-catenin in renal proximal tubule cells. Am. J. Physiol. Renal. Physiol., 2010, 298(5), F1263-1275.
64. Yang, Z.; Sun, L.; Nie, H.; Liu, H.; Liu, G.; Guan, G. Connective tissue growth factor induces tubular epithelial to mesenchymal transition through the activation of canonical Wnt signaling in vitro. Ren. Fail., 2015, 37(1), 129-135.
65. Dai, C.; Stolz, D.B.; Kiss, L.P.; Monga, S.P.; Holzman, L.B.; Liu, Y. Wnt/β-catenin signaling promotes podocyte dysfunction and abuminuria. J. Am. Soc. Nephrol., 2009, 20(9), 1997-2008.
66. Kato, H.; Gruenwald, A.; Suh, J.H.; Miner, J.H.; Barisoni-Thomas, L.; Taketo, M.M.; Faul, C.; Millar, S.E.; Holzman, L.B.; Susztak, K. Wnt/β-Catenin Pathway in Podocytes Integrates Cell Adhesion, Differentiation, and Survival. J. Biol. Chem., 2011, 286(29), 26003-26015.
67. Li, Z.; Xu, J.; Xu, P.; Liu, S.; Yang, Z. Wnt/β-catenin signalling pathway mediates high glucose induced cell injury through activation of TRPC6 in podocytes. Cell Prolif., 2013, 46(1), 76-85.
68. Laplante, M.; Sabatini, D.M. mTOR signaling in growth control and disease. Cell, 2012, 149(2), 274-293.
69. Polak, P.; Hall, M.N. mTOR and the control of whole body metabolism. Curr. Opin. Cell Biol., 2009, 21(2), 209-218.
70. Brosius, F.C.; Khoury, C.C.; Buller, C.L.; Chen, S. Abnormalities in signaling pathways in diabetic nephropathy. Expert. Rev. Endocrinol. Metab., 2010, 5(1), 51-64.
71. Kasinath, B.S.; Mariappan, M.M.; Sataranatarajan, K.; Lee, M.J.; Feliers, D. mRNA translation: unexplored territory in renal science. J. Am. Soc. Nephrol., 2006, 17(12), 3281-3292.
72. Mariappan, M.M.; Feliers, D.; Mummidi, S.; Choudhury, G.G.; Kasinath, B.S. High glucose, high insulin, and their combination rapidly induce laminin-beta1 synthesis by regulation of mRNA translation in renal epithelial cells. Diabetes, 2007, 56(2), 476-485.
73. Lieberthal, W.; Levine, J.S. The role of the mammalian target of rapamycin (mTOR) in renal disease. J. Am. Soc. Nephrol., 2009, 20(12), 2493-2502.
74. Lioberas, N.; Cruzado, J.M.; Franquesa, M.; Herrero-Fresneda, I.; Torras, J.; Alperovich, G.; Rama, I.; Vidal, A.; Grinyo, J.M. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease. J. Am. Soc. Nephrol., 2006, 17(5), 1395-1404.
75. Mori, H.; Inoki, K.; Masutani, K.; Wakabayashi, Y.; Komai, K.; Nakagawa, R.;Guan, K.L.; Yoshimura, A. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem. Biophys. Res. Commun., 2009, 384(4), 471-475.
76. Sakaguchi, M.; Isono, M.; Isshiki, K.; Sugimoto, T.; Koya, D.; Kashiwagi, A. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem. Biophys. Res. Commun., 2006, 340(1), 296-301.
77. Yang, Y.; Wang, J.; Qin, L.; Shou, Z.; Zhao, J.; Wang, H.; Chen, Y.; Chen, J. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am. J. Nephrol., 2007, 27(5), 495- 502.
78. Grahammer, F.; Wanner, N.; Huber, T.B. mTOR controls kidney epithelia in health and disease. Nephrol. Dial. Transplant, 2014, 29 Suppl 1, i9-i18.
79. Sataranatarajan, K.; Mariappan, M.M.; Lee, M.J.; Feliers, D.; Choudhury, G.G.; Barnes, J.L.; Kasinath, B.S. Regulation of elongation phase of mRNA translation in diabetic nephropathy: Amelioration by rapamycin. Am. J. Pathol., 2007, 171(6), 1733-1742.
80. Mavroeidi, V.; Petrakis, I.; Stylianou, K.; Katsarou, T.; Giannakakis, K.; Perakis, K.; Vardaki, E.; Stratigis, S.; Ganotakis, E.; Papavasiliou, S., Daphnis, E. Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy. J. Histochem. Cytochem., 2013, 61(6), 433-443.
81. Flaquer, M.; Lloberas, N.; Franquesa, M.; Torras, J.; Vidal, A.; Rosa, J.L.; Herrero-Fresneda, I.; Grinyo, J.M.; Cruzado, J.M. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life Sci., 2010, 87(5- 6), 147-153.
82. Habib, S.L. Alterations in tubular epithelial cells in diabetic nephropathy. J. Nephrol., 2013, 26(5), 865-869.
83. Lu, M.K.; Gong, X.G.; Guan, K.L. mTOR in podocyte function Is rapamycin good for diabetic nephropathy? Cell Cycle, 2011, 10(20), 3415-3416.
84. Gödel, M.; Hartleben, B.; Herbach, N.; Liu, S.; Zschiedrich, S.; Lu, S.; Debreczeni-Mór, A.; Lindenmeyer, M.T.; Rastaldi, M.P.; Hartleben, G.; Wiech, T.; Fornoni, A.; Nelson, R.G.; Kretzler, M.; Wanke, R.; Pavenstädt, H.; Kerjaschki, D.; Cohen, C.D.; Hall, M.N.; Ruegg, M.A.;Inoki, K.; Walz, G.; Huber, T.B. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J. Clin. Invest., 2011, 121(6), 2197-2209.
85. Inoki, K.; Mori, H.; Wang, J.; Suzuki, T.; Hong, S.; Yoshida, S.; Blattner, S.M.; Ikenoue, T.; Ruegg, M.A.; Hall, M.N.; Kwiatkowski, D.J.; Rastaldi, M.P.; Huber, T.B.; Kretzler, M.; Holzman, L.B.; Wiggins, R.C.; Guan, K.L. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J. Clin. Invest., 2011, 121(6), 2181-2196.
86. Bianchi, M.E. DAMPs, PAMPs and alarmins: All we need to know about danger. J. Leukoc., Biol. 2007, 81(1), 1-5.
87. Robson, M.G. Toll-like receptors and renal disease. Nephron Exp. Nephrol., 2009, 113(1), e1-7.
88. Lin, M.;Tang, S.C. Toll-like receptors: sensing and reacting to diabetic injury in the kidney. Nephrol. Dial. Transplant, 2014, 29(4), 746-754.
89. Mudaliar, H.; Pollock, C.; Panchapakesan, U. Role of Toll-like receptors in diabetic nephropathy. Clin. Sci. (Lond)., 2014, 126(10), 685-694.
90. Tang, S.C.; Yiu, W.H; Lin, M.; Lai, K.N. Diabetic nephropathy and proximal tubular damage. J. Ren. Nutr., 2015, 25(2), 230-233.
91. Ma, J.; Wu, H.; Zhao, C.Y.; Panchapakesan, U.; Pollock, C.; Chadban, S.J. Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. Int. J. Clin. Exp. Pathol., 2014, 7(2), 481-495.
92. Saurus, P.; Kuusela, S.; Lehtonen, E.; Hyvonen, M.E.; Ristola, M.; Fogarty, C.L.; Tienari, J.; Lassenius, M.I.; Forsblom, C.; Lehto, M.; Saleem, M.A.; Groop, P.H.; Holthofer, H.; Lehtonen, S. Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. Cell Death Dis., 2015, 6, e1752.
93. Devaraj, S.; Tobias, P.; Kasinath, B.S.; Ramsamooj, R.; Afify, A.; Jialal, I. Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler. Thromb. Vasc. Biol., 2011, 31(8), 1796-1804.
94. Campbell, M.T.; Hile, K.L.; Zhang, H.; Asanuma, H.; Vanderbrink, B.A.; Rink, R.R.; Meldrum, K.K. Toll-like receptor 4: A novel signaling pathway during renal fibrogenesis. J. Surg. Res., 2011, 168(1), e61-69.
95. Pulskens, W.P.; Rampanelli, E.; Teske, G.J.; Butter, L.M.; Claessen, N.; Luirink, I.K.; van der Poll, T.; Florquin, S.; and Leemans, J.C. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J. Am. Soc. Nephrol., 2010, 21(8), 1299-1308.
96. Ma, J.; Chadban, S.J.; Zhao, C.Y.; Chen, X.; Kwan, T.; Panchapakesan, U.; Pollock, C.A.; Wu, H. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One, 2014, 9(5), e97985.
97. Kuwabara, T.; Mori, K.; Mukoyama, M.; Kasahara, M.; Yokoi, H., Saito, Y.; Ogawa, Y.; Imamaki, H.; Kawanishi, T.; Ishii, A.;Koga, K.; Mori, K.P.; Kato, Y.; Sugawara, A.; Nakao, K. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia, 2012, 55(8), 2256-2266.
98. Jialal, I.; Major, A.M.; Devaraj, S.J. Global Toll-like receptor 4 knockout results in decreased renal inflammation, fibrosis and podocytopathy. J. Diabetes Complications, 2014, 28(6), 755-761.
99. Kaur, H.; Chien, A.; and Jialal, I. Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: Relevance to diabetic nephropathy. Am. J. Physiol. Renal Physiol., 2012, 303(8), F1145-1150.
100. Lin, M.; Yiu, W.H.; Wu, H.J.; Chan, L.Y.; Leung, J.C.; Au, W.S.; Chan, K.W.; Lai, K.N.; Tang, S.C. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J. Am. Soc. Nephrol., 2012, 23(1), 86-102.
101. Cha, J.J.; Hyun, Y.Y.; Lee, M.H.; Kim, J.E.; Nam, D.H.; Song, H.K.; Kang, Y.S.; Lee, J.E.; Kim, H.W.; Han, J.Y.; Cha, D.R. Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology, 2013, 154(6), 2144-2155.
102. Takai, Y.; Sasaki, T.; Matozaki, T. Small GTP-binding proteins. Physiol. Rev., 2001, 81(1), 153-208.
103. Carmena, A. A big new job for small GTPases. Small GTPases, 2012, 3(3), 159-162.
104. Reuther, G.W.; Der, C.J. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr. Opin. Cell. Biol., 2000, 12(2), 157-165.
105. Rufanova, V.A.; Alexanian, A.; Wakatsuki, T.; Lerner, A.; Sorokin, A. Pyk2 mediates endothelin-1 signaling via p130Cas/BCAR3 cascade and regulates human glomerular mesangial cell adhesion and spreading. J. Cell Physiol., 2009, 219(1), 45-56.
106. Huang, S.K.; Wettlaufer, S.H.; Chung, J.; Peters-Golden, M. Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1. Am. J. Respir. Cell Mol. Biol., 2008, 39(4), 482-489.
107. Lin, S.; Chugh, S.; Pan, X.; Wallner, E.I.; Wada, J.; Kanwar, Y.S. Identification of up-regulated Ras-like GTPase, Rap1b, by suppression subtractive hybridization. Kidney Int., 2001, 60(6), 2129-2141.
108. Wallner, E.I.; Wada, J.; Lin, S.; Pan, X.; Reddy, J.K.; Chugh, S.S.; Kanwar, Y.S. Renal gene expression in embryonic and newborn diabetic mice. Exp. Nephrol., 2002, 10(2), 130-138.
109. Lin, S.; Sahai, A.; Chugh, S.S.; Pan, X.; Wallner, E.I.; Danesh, F.R.; Lomasney, J.W.; Kanwar, Y.S. High glucose stimulates synthesis of fibronectin via a novel protein kinase C, Rap1b, and BRaf signaling pathway. J. Biol. Chem., 2002, 277(44), 41725- 41735.
110. Xiao, L.; Zhu, X.; Yang, S.; Liu, F.; Zhou, Z.; Zhan, M.; Xie, P.; Zhang, D.; Li, J.; Song, P.; Kanwar, Y.S.; Sun, L.Rap1 ameliorates renal tubular injury in diabetic nephropathy. Diabetes, 2014, 63(4), 1366-1380.
111. Sun, L.; Xie, P.; Wada, J.; Kashihara, N.; Liu, F.Y.; Zhao, Y.; Kumar, D.; Chugh, S.S.; Danesh, F.R.; Kanwar, Y.S. Rap1b GTPase ameliorates glucose-induced mitochondrial dysfunction. J. Am. Soc. Nephrol., 2008, 19(12), 2293-2301.
112. Lin, C.L.; Wang, F.S.; Kuo, Y.R.; Huang, Y.T.; Huang, H.C.; Sun, Y.C.; Kuo, Y.H. Ras modulation of superoxide activates ERKdependent fibronectin expression in diabetes-induced renal injuries. Kidney Int., 2006, 69(9), 1593-1600.
113. Xu, D.; Kyriakis, J.M. Phosphatidylinositol 3'-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products. J. Biol. Chem., 2003, 278(41), 39349- 39355.
114. Zhou, H.; Yao, C.; Bian, A.; Qian, J.; Zhao, X.; Zhao, Y.; Wang, W.; Xing, C. The Ras GTPase-activating-like protein IQGAP1 is downregulated in human diabetic nephropathy and associated with ERK1/2 pathway activation. Mol. Cell Biochem., 2014, 391(1-2), 21-25.
115. Komers, R. Rho kinase inhibition in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens., 2011, 20(1), 77-83.
116. David, M.; Petit, D.; Bertoglio, J. Cell cycle regulation of Rho signaling pathways. Cell Cycle, 2012, 11(16), 3003-3010.
117. Liao, J.K.; Seto, M.; Noma, K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol., 2007, 50(1), 17-24.
118. Komers, R. Rho kinase inhibition in diabetic kidney disease. Br. J. Clin. Pharmacol., 2013, 76(4), 551-559.
119. Bach, L.A. Rho kinase inhibition: A new approach for treating diabetic nephropathy? Diabetes, 2008, 57(3), 532-533.
120. Peng, F.; Wu, D.; Gao, B.; Ingram, A.J.; Zhang, B.; Chorneyko, K.; McKenzie, R.; Krepinsky, J.C. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes, 2008, 57(6), 1683- 1692.
121. Ma, D.W.; Wang, Q.Y.; Ma, X.Y.; Li, J.; Guan, Q.H.; Fu, Y. The effect of fasudil via Rho/ROCK signaling pathway on the inflammation and fibrosis in human mesangial cells in high glucose medium. Zhonghua Nei Ke Za Zhi, 2011, 50(7), 580-584.
122. Ma, D.W.; Wang, Q.Y.; Chen, Q.G.; Wu, D.; Wang, J.; Hou, L.L. Effects of inhibiting RhoA by Stealth RNA on high glucoseinduced RhoA/ROCK signaling pathway in human mesangial cells. Zhonghua Yi Xue Za Zhi, 2011, 91(20), 1417-1421.
123. Xie, X.; Peng, J.; Chang, X.; Huang, K.; Huang, J.; Wang, S.; Shen, X.; Liu, P.; Huang, H. Activation of RhoA/ROCK regulates NF-kappaB signaling pathway in experimental diabetic nephropathy. Mol. Cell Endocrinol., 2013, 369(1-2), 86-97.
124. Gu, L.; Gao, Q.; Ni, L.; Wang, M.; Shen, F. Fasudil inhibits epithelial- myofibroblast transdifferentiation of human renal tubular epithelial HK-2 cells induced by high glucose. Chem. Pharm. Bull. (Tokyo)., 2013, 61(7), 688-694.
125. Kolavennu, V.; Zeng, L.; Peng, H.; Wang, Y.; Danesh, F.R. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes, 2008, 57(3), 714-723.
126. Kikuchi, Y.; Yamada, M.; Imakiire, T.; Kushiyama, T.; Higashi, K.; Hyodo, N.; Yamamoto, K.; Oda, T.; Suzuki, S.; Miura, S. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J. Endocrinol., 2007, 192(3), 595-603.
127. Wu, G.; Xu, M.; Xu, K.; Hu, Y. Benidipine protects kidney through inhibiting ROCK1 activity and reducing the epitheliummesenchymal transdifferentiation in type 1 diabetic rats. J. Diabetes Res., 2013, 2013, 174526.
128. Xie, X.; Chang, X.; Chen, L.; Huang, K.; Huang, J.; Wang, S.; Shen, X.; Liu, P.; Huang, H. Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting activation of RhoA/ROCK signaling. Mol. Cell Endocrinol., 2013, 381(1-2), 56-65.
129. Gojo, A.; Utsunomiya, K.; Taniguchi, K.; Yokota, T.; Ishizawa, S.; Kanazawa, Y.; Kurata, H.; Tajima, N. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol., 2007, 568(1-3), 242-247.
130. Wang, S.; Denichilo, M.; Brubaker, C.; Hirschberg, R. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int., 2001, 60(1), 96-105.
131. Wang, B.; Komers, R.; Carew, R.; Winbanks, C.E.; Xu, B.; Herman- Edelstein, M.; Koh, P.; Thomas, M.; Jandeleit-Dahm, K.; Gregorevic, P.; Cooper, M.E.; Kantharidis, P. Suppression of microRNA- 29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J. Am. Soc. Nephrol., 2012, 23(2), 252- 265.
132. Ishizawa, S.; Takahashi-Fujigasaki, J.; Kanazawa, Y.; Matoba, K.; Kawanami, D.; Yokota, T.; Iwamoto, T.; Tajima, N.; Manome, Y.; Utsunomiya, K. Sphingosine-1-phosphate induces differentiation of cultured renal tubular epithelial cells under Rho kinase activation via the S1P2 receptor. Clin. Exp. Nephrol., 2014, 18(6), 844-852.
133. Danesh, F.R.; Sadeghi, M.M.; Amro, N.; Philips, C.; Zeng, L.; Lin, S.; Sahai, A.; Kanwar, Y.S. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(12), 8301-8305.
134. Xie, X.; Chen, C.; Huang, K.; Wang, S.; Hao, J.; Huang, J.; Huang, H. RhoA/rho kinase signaling reduces connexin43 expression in high glucose-treated glomerular mesangial cells with zonula occludens- 1 involvement. Exp. Cell Res., 2014, 327(2), 276-286.
135. Wang, W.; Wang, Y.; Long, J.; Wang, J.; Haudek, S.B.; Overbeek, P.; Chang, B.H.; Schumacker, P.T.; Danesh, F.R. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab., 2012, 15(2), 186-200.
136. Zerial, M.; McBride, H. Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol., 2001, 2(2), 107-117.
137. Speight, P.; Silverman, M. Diacylglycerol-activated Hmunc13 serves as an effector of the GTPase Rab34. Traffic, 2005, 6(10), 858-865.
138. Goldenberg, N.M.; Silverman, M. Rab34 and its effector munc13-2 constitute a new pathway modulating protein secretion in the cellular response to hyperglycemia. Am. J. Physiol. Cell Physiol., 2009, 297(4), C1053-C1058.
139. Turgut, F.; Bolton, W.K. Potential new therapeutic agents for diabetic kidney disease. Am. J. Kidney Dis., 2010, 55(5), 928-940.